Product image of Meriofert Set (Luteinising Hormone (Human), Follicle-Stimulating Hormone) supplied by GNH India

Meriofert Set

Active Ingredient:
Luteinising Hormone (Human), Follicle-Stimulating Hormone
Origin:
EU

Meriofert Set (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Human Menopausal Gonadotropin (hMG), the active ingredient in Meriofert Set, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It stimulates ovarian follicular development to induce ovulation in women and supports spermatogenesis in men.

GNH India supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this injectable fertility agent. Customers benefit from consistent product availability and regulatory compliance across EU and global markets.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Meriofert Set, a gonadotropin used in reproductive medicine, is indicated for the following clinical situations:
  • Induction of ovulation in anovulatory women: promotes follicular growth and estrogen production to achieve a timed ovulatory response.
  • Controlled ovarian stimulation for assisted reproductive technologies: enhances development of multiple follicles, increasing the number of oocytes retrieved for IVF or ICSI procedures.
  • Stimulation of spermatogenesis in male hypogonadism: provides LH and FSH activity to stimulate Leydig and Sertoli cells, improving testosterone levels and sperm output.

How It Works

  • Meriofert Set contains a purified mixture of human luteinising hormone and follicle‑stimulating hormone. The FSH component binds to FSH receptors on ovarian granulosa cells, stimulating follicular maturation and estradiol synthesis. The LH component activates LH receptors on theca and Leydig cells, promoting androgen production that is aromatised to estrogen in women and supports testosterone synthesis and spermatogenesis in men.

Side Effects

Like other gonadotropin preparations, Meriofert Set may be associated with a range of adverse reactions.

Common Side Effects

  • Injection site pain or bruising
  • Mild abdominal discomfort or bloating
  • Nausea or vomiting
  • Headache
  • Mild ovarian hyperstimulation (e.g., mild ovarian enlargement)

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (severe)
  • Multiple pregnancy
  • Severe allergic reaction (anaphylaxis)
  • Thromboembolic events
  • Ectopic pregnancy

Precautions & Warnings

Prior to initiating therapy with Meriofert Set, several precautionary measures should be observed.

  • Pregnancy testing: confirm non‑pregnant status before starting treatment.
  • Baseline ovarian assessment: perform ultrasound to evaluate follicle count and size.
  • Monitor estradiol levels: regular blood tests to detect excessive response.
  • Adjust dose in patients with ovarian cysts or polycystic ovary syndrome.
  • Caution in patients with thromboembolic risk: assess history before use.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert Set can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • GnRH agonists: may amplify ovarian response and increase risk of severe hyperstimulation.
  • Estrogen‑containing contraceptives: antagonize gonadotropin action, reducing effectiveness.
  • Anticoagulants: heightened risk of bleeding at injection sites.

Moderate Interactions (Monitor Closely)

  • Oral hypoglycemic agents: monitor blood glucose as hormonal changes can affect control.
  • Corticosteroids: may alter ovarian response, requiring dose adjustment.
  • Thyroid hormone therapy: assess thyroid function as gonadotropins can influence metabolism.

Frequently Asked Questions

Meriofert Set is a human menopausal gonadotropin (hMG) injectable used in fertility treatment to induce ovulation in women with anovulatory disorders, to stimulate multiple follicle development for assisted reproductive technologies, and to promote spermatogenesis in men with hypogonadism.

The preparation contains both follicle‑stimulating hormone (FSH) and luteinising hormone (LH). FSH binds to receptors on ovarian granulosa cells, driving follicle growth and estrogen synthesis, while LH activates theca and Leydig cells, leading to androgen production that is converted to estrogen in women or supports testosterone and sperm production in men.

The dose of Meriofert Set is individualized; a qualified prescriber determines the amount and schedule based on the patient’s clinical condition, response to therapy, and monitoring results. No fixed regimen is provided in public information.

Meriofert Set is intended for use before conception to facilitate ovulation; it is not administered during an established pregnancy. Safety in breastfeeding has not been established, and the prescriber should evaluate risks versus benefits before use in lactating women.

To place an order, submit an enquiry on the Meriofert Set product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Compared with recombinant FSH products, hMG provides a combination of FSH and LH activity in a single preparation, which can be advantageous for patients who require both hormones for optimal follicular response. Recombinant preparations contain only FSH and may require separate LH supplementation, while hMG offers a more physiologic hormone ratio.

Meriofert Set must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

The medication is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a healthcare professional using aseptic technique, typically in the gluteal muscle or abdominal wall, according to the dosing schedule prescribed.

The most serious adverse events include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, abdominal pain, and fluid accumulation, and the possibility of multiple pregnancy. Rarely, anaphylactic reactions or thromboembolic events may occur, requiring immediate medical attention.

Meriofert Set is contraindicated in patients with known hypersensitivity to hMG

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Luteinising Hormone (Human), Follicle-Stimulating Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT